Aharon Schwartz
CIK: 0001625184
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
Award(A)DirectStock Options (Right to Buy)
17K shares- - Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
Award(A)DirectRestricted Stock Units
8.5K shares- - Sep 3, 2025PLX
Protalix BioTherapeutics, Inc.
Award(A)Indirect7.5K shares- - Jun 10, 2025PLX
Protalix BioTherapeutics, Inc.
Purchase(P)Direct129K shares at avg. $1.60$206K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 |  PLX Protalix BioTherapeutics, Inc. | Award(A) Stock Options (Right to Buy) | 17,000 | - | - | Direct |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | Award(A) Restricted Stock Units | 8,500 | - | - | Direct |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | Award(A) | 7,500 | - | - | Indirect |
| Jun 10, 2025 | PLX Protalix BioTherapeutics, Inc. | Purchase(P) | 129,000 | $1.60 | $205,884 | Direct |
1-4 of 4 transactions
About Schwartz Aharon
Schwartz Aharon (SEC CIK 0001625184) files insider reports with the SEC as Director of Protalix BioTherapeutics, Inc. (PLX) and Director of BioLineRx Ltd. (BLRX).
Signal8 holds 4 ownership filings by Schwartz Aharon (1 Form 3, 3 Form 4), filed between Aug 12, 2025 and Sep 9, 2026. Those filings report 4 transactions, from Jun 10, 2025 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Schwartz Aharon's filings is in CARMIEL.
Recent filings by Schwartz Aharon
Other insiders filing for Protalix BioTherapeutics, Inc. (PLX)
- Naos Yaron, Sr. VP & COO
- Melincoff Gwen A, Director
- Elze Christian, Director
- Boudes Pol F, Director
- Bar-Shalev Amos, Director
- Bashan Dror, PRESIDENT AND CEO